Skip to content

Main Navigation

Clinical Study

ABBV-154: A Study Drug to Improve Crohns Disease Symptoms

ABBV-154 is an anti-body study drug to help people with Crohn's disease reduce inflammation with fewer side effects. Scientists and doctors do not know the safety and effectiveness of ABBV-154. Research is needed to learn if it may be approved and used to improve the health of people with Crohn's disease.


For more information contact:

Julie Will
  (801) 587-9060

IRB#: IRB_00150107 | PI: John Valentine | Department: GASTROENTEROLOGY | Approval Date: 2022-06-15 06:00:00
Specialties: Gastroenterology

Who can participate?

 Gender: All

 Age: Over 18 years old

 Volunteers: Volunteers with special conditions

 Location: In Person

Inclusion Criteria:

  • Males and Females ages 18-75
  • BMI more than 18.0 and less than 39.9
  • Confirmed diagnosis of Crohns disease with inflammation for more than 3 months
  • No clinical history of substance abuse within the last 12 months
  • Attend in-person at University of Utah

Exclusion Criteria:

  • Pregnant, breastfeeding, or considering pregnancy or fathering
  • Non-use of protocol-specified birth control for childbearing female
  • Non-use of protocol-specified contraceptive for sexually active male
  • History of protocol-specified infections, diseases, and/or disorders
  • Prior exposure to ABBV-154

Will I be paid for my time?


Last Updated: 4/5/21